<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TIH</journal-id>
<journal-id journal-id-type="hwp">sptih</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Ind Health</journal-id>
<journal-title>Toxicology and Industrial Health</journal-title>
<issn pub-type="ppub">0748-2337</issn>
<issn pub-type="epub">1477-0393</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0748233712436643</article-id>
<article-id pub-id-type="publisher-id">10.1177_0748233712436643</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of levosimendan injection on oxidative stress of rat myocardium</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Başel</surname>
<given-names>Halil</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233712436643">1</xref>
<xref ref-type="corresp" rid="corresp1-0748233712436643"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kavak</surname>
<given-names>Servet</given-names>
</name>
<xref ref-type="aff" rid="aff2-0748233712436643">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Demir</surname>
<given-names>Halit</given-names>
</name>
<xref ref-type="aff" rid="aff3-0748233712436643">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meral</surname>
<given-names>Ismail</given-names>
</name>
<xref ref-type="aff" rid="aff4-0748233712436643">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ekim</surname>
<given-names>Hasan</given-names>
</name>
<xref ref-type="aff" rid="aff5-0748233712436643">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bektaş</surname>
<given-names>Hava</given-names>
</name>
<xref ref-type="aff" rid="aff2-0748233712436643">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0748233712436643">
<label>1</label>Department of Cardiovascular Surgery, Bezmi Alem Foundation University Hospital, İstanbul, Turkey</aff>
<aff id="aff2-0748233712436643">
<label>2</label>Department of Biophysics, Yuzuncu Yil University, Van, Turkey</aff>
<aff id="aff3-0748233712436643">
<label>3</label>Department of Chemistry, Division of Biochemistry, Yuzuncu Yil University, Van, Turkey</aff>
<aff id="aff4-0748233712436643">
<label>4</label>Department of Physiology, Yuzuncu Yil University, Van, Turkey</aff>
<aff id="aff5-0748233712436643">
<label>5</label>Department of Cardiovascular Surgery, Yuzuncu Yil University, Van, Turkey</aff>
<author-notes>
<corresp id="corresp1-0748233712436643">Halil Başel, Department of Cardiovascular Surgery, Bezmi Alem Hospital, İstanbul 64000, Turkey. Email: <email>hbasel@mynet.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>29</volume>
<issue>5</issue>
<fpage>435</fpage>
<lpage>440</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>This experiment was designed to investigate the effect of levosimendan injection on lipid peroxidation product malondialdehyde (MDA) and antioxidant glutathione (GSH) levels, and activities of antioxidant enzymes in myocardium of rats. Twenty male Wistar-albino rats were divided randomly into 2 study groups, each consisting of 10 rats. The animals in the first group were not treated with drug and served as control. It was found that the MDA and GSH levels decreased in levosimendan injected group. Superoxide dismutase, glutathione peroxidase, catalase and carbonic anhydrase enzyme activities were lower in levosimendan injected group than controls. It was concluded that lower tissue free radical level caused by levosimendan injection led to a lower antioxidant enzymes synthesis in the body and a decrease in the antioxidant enzyme activity and free radical scavenger level in myocardium of rat.</p>
</abstract>
<kwd-group>
<kwd>Levosimendan</kwd>
<kwd>oxidative stress</kwd>
<kwd>antioxidant</kwd>
<kwd>myocardium</kwd>
<kwd>rat</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0748233712436643">
<title>Introduction</title>
<p>Levosimendan is an inotropic agent used in the management of acute decompensated heart failure. It mediates its cardiac effect by the Ca<sup>2+</sup> sensitization of the contractile protein troponin C (<xref ref-type="bibr" rid="bibr9-0748233712436643">Innes and Wagstaff, 2003</xref>). Levosimendan binds with the Ca<sup>2+</sup>-saturated N-terminal domain of troponin C in cardiac muscle and stabilizes the troponin molecule with subsequent prolongation of its effect on the contractile proteins (<xref ref-type="bibr" rid="bibr7-0748233712436643">Haikala et al., 1995</xref>; Innes and Wagstaff, 2003). Besides increasing the strength of cardiac contractions, levosimendan also exerts vasodilatory effects through the opening of the ATP-dependent K<sup>+</sup> channels (<xref ref-type="bibr" rid="bibr10-0748233712436643">Kaheinen et al., 2001</xref>).</p>
<p>Aerobic organisms are protected from oxygen toxicity by a natural antioxidant defense system involving enzymatic and nonenzymatic mechanisms (<xref ref-type="bibr" rid="bibr20-0748233712436643">Özer and Kaman, 2007</xref>). The increased formation of reactive oxygen species (ROS) and decreased antioxidant defense is defined as oxidative stress, which is widely recognized as an important feature of many diseases. Superoxide dismutase (SOD) and catalase (CAT) are cellular antioxidants, which protect cells from oxidative stress. Lipid peroxidation (LPO) is one of the most important expressions of oxidative stress induced by ROS. Malondialdehyde (MDA) is an indicator of LPO and increases in various diseases (<xref ref-type="bibr" rid="bibr12-0748233712436643">Kang et al., 1996</xref>; <xref ref-type="bibr" rid="bibr19-0748233712436643">Nordberg and Arner, 2001</xref>). CAT is mainly a heme-containing enzyme. The predominant subcellular localization of enzyme is peroxisomes, in which it catalyzes the dismutation of hydrogen peroxide to water and molecular oxygen. CAT activity is highest in the liver, relatively high in kidney and very low in heart (Nordberg and Arner, 2001; <xref ref-type="bibr" rid="bibr32-0748233712436643">Yazar et al., 2004</xref>).</p>
<p>Congestive or dilated cardiomyopathy refers to weakened cardiac muscle that is unable to pump strongly enough to empty the heart properly in each beat. In restrictive cardiomyopathy, the muscle becomes so stiffened and inextensible that the heart cannot fill properly between beats. The degeneration of myocardium associated with muscular dystrophy is often accompanied by cardiomyopathy (<xref ref-type="bibr" rid="bibr17-0748233712436643">Markova et al., 1995</xref>; Colledge et al., 2010).</p>
<p>This experiment was designed to investigate the effects of inotropic agent levosimendan on myocardial MDA and glutathione (GSH) levels, and SOD, CAT, glutathione peroxidase<bold> </bold>(GSH-Px) and c<italic>arbonic anhydrase</italic> (CA) enzyme activities in rats. In another words, it was aimed to investigate whether in addition to its positive inotropic action, levosimendan could also ameliorate the LPO-related disturbances in myocardium of rats.</p>
</sec>
<sec id="section2-0748233712436643" sec-type="methods">
<title>Methods</title>
<sec id="section3-0748233712436643">
<title>Treatment of animals</title>
<p>Eighteen male Wistar-albino rats, aging approximately 6 months (280–300 g) were obtained from the Animal Laboratory of Yuzuncu Yil University. Rats were housed in standard cages. A 12-h light/dark cycle was maintained and the rats were feed ad libitum.</p>
<p>The animals were divided randomly into 2 study groups, each consisting of 10 rats. The animals in the first group were not treated with drug and served as control. Animals in the second group were administered intraperitonally (i.p.) with 24 μg/kg levosimendan (Simdax, Abbott, Turkey). Animals in both groups were killed 3 days after the drug treatment and their hearts were harvested for the determination of myocardium oxidant/antioxidant status.</p>
</sec>
<sec id="section4-0748233712436643">
<title>Biochemical analysis</title>
<p><italic>Measurement of MDA level</italic>. A tissue specimen of 50 mg was homogenized in 0.15 mol/L KCl. After the homogenate had been centrifuged at 1600<italic> g</italic>, the MDA levels in the supernatant of tissue homogenate were determined by thiobarbituric acid (TBA) reaction according to the method of <xref ref-type="bibr" rid="bibr31-0748233712436643">Yagi (1994</xref>). The principle of the method is based on measuring the absorbance of the pink color produced by the interaction of TBA with MDA at 530 nm. Values were expressed as mg/dl.</p>
<p><italic>Measurements of SOD and GSH-Px enzyme activities</italic>. The tissues were homogenized in physiological saline (1 g in 5 ml) using a homogenizer (B. Braun MelsungenAG 853202, Germany) and then centrifuged at 4000 <italic>g</italic> for 20 min (Heraous Labofur 200, Germany). GSH-Px activity was measured by observing the changes in nicotinamide adenine dinucleotide phosphate absorbance at 340 nm (<xref ref-type="bibr" rid="bibr1-0748233712436643">Aebi, 1974</xref>) and by measuring the decrease in H<sub>2</sub>O<sub>2</sub> absorbance at 240 nm. SOD activity was measured by the method based on nitroblue tetrazolium (NBT) reduction rate. One unit of SOD activity was expressed as the enzyme protein amount causing 50% inhibition in NBT reduction rate (<xref ref-type="bibr" rid="bibr3-0748233712436643">Durak et al., 1996</xref>).</p>
<p><italic>Measurement of GSH level</italic>. The GSH levels of tissues were measured at 412 nm using the method of <xref ref-type="bibr" rid="bibr1-0748233712436643">Aebi (1974</xref>). The samples were precipitated with 50% TCA and then centrifuged at 1000 <italic>g</italic> for 5 min. The reaction mixture contained 0.5 ml of supernatant, 2.0 ml of Tris-ethylenediaminetetraacetic acid buffer (0.2 M; pH 8.9) and 0.1 ml of 0.01 M 5,5′-dithio-bis (2-nitrobenzoic acid). The solution was kept at room temperature for 5 min and then read at 412 nm on the spectrophotometer.</p>
<p><italic>Measurement of CAT enzyme activity.</italic> Biochemical analysis of tissue CAT activity was performed with a method described by <xref ref-type="bibr" rid="bibr25-0748233712436643">Sedlak and Lindsay (1968</xref>). Briefly, the supernatant (0.1 ml) was added to a quartz cuvette containing 2.95 ml of 19 mmol/L H<sub>2</sub>O<sub>2</sub> solution prepared in potassium phosphate buffer (0.05 M, pH 7.00). The change in absorbance was monitored at 240 nm for 5 min using a spectrophotometer (Shimadzu UV-1201, Japan).</p>
<p><italic>Measurement of CA enzyme activity.</italic> CA activity was assayed by hydration of CO<sub>2</sub>. The hydration of CO<sub>2</sub> was measured by the method of Rickli and Wilbur-Anderson with bromothymol blue as indicator (<italic>Topçuoglu et al., <xref ref-type="bibr" rid="bibr28-0748233712436643">2009</xref>
</italic>).</p>
</sec>
<sec id="section5-0748233712436643">
<title>Statistical analysis</title>
<p>The results were expressed as mean ± standard deviation (SD). Kruskal–Wallis (which is nonparametric) test was used for the comparison of groups. When significant differences were observed (<italic>p</italic> &lt; 0.05), Tukey multiple comparison test was used to determine the differences between groups. Statistical analyses were carried out using the SPSS<sup>®</sup> statistical software package (SPSS for Windows version 13.0, SPSS Inc., Chicago, Illinois, USA).</p>
</sec>
</sec>
<sec id="section6-0748233712436643">
<title>Results</title>
<p>The tissue MDA level, which is as an indicator of oxidative stress, was 84.628 ± 6.05 in control group and 64.58 ± 5.22 in the levosimendan group, indicating a significantly lower (<italic>p</italic> &lt; 0.001) MDA level in levosimendan group (<xref ref-type="fig" rid="fig1-0748233712436643">Figure 1</xref>). The protective enzyme levels including GSH, SOD, GSH-Px and CAT, which play great roles in cellular defense against oxidative stress (<xref ref-type="fig" rid="fig2-0748233712436643">Figures 2</xref>, <xref ref-type="fig" rid="fig3-0748233712436643">3</xref>, <xref ref-type="fig" rid="fig4-0748233712436643">4</xref>, <xref ref-type="fig" rid="fig5-0748233712436643">5</xref>), were found to be 73.597 ± 2.52, 38.903 ± 5.93, 201.215 ± 2.45 and 88.565 ± 1.34 in the control group, and 62.612 ± 5.01, 11.985 ± 3.15, 148.307 ± 2.48 and 74.005 ± 3.14 in the levosimendan group, respectively. The comparison of these data revealed that the protective enzyme levels were significantly lower (<italic>p</italic> &lt; 0.001) in the levosimendan group. However, there was no significant difference in CA level between the control group (0.422 ± 0.039) and the levosimendan group (0.255 ± 0.051; <italic>p</italic> &lt; 0.001; <xref ref-type="fig" rid="fig6-0748233712436643">Figure 6</xref>).</p>
<fig id="fig1-0748233712436643" position="float">
<label>Figure 1. </label>
<caption>
<p>Malondialdehyde (MDA) level in the myocardium of control and levosimendan-treated rats. *Denotes a significant difference (<italic>p</italic> &lt; 0.001) between treatment and control groups.</p>
</caption>
<graphic xlink:href="10.1177_0748233712436643-fig1.tif"/>
</fig>
<fig id="fig2-0748233712436643" position="float">
<label>Figure 2.</label>
<caption>
<p>Glutathione (GSH) level in the myocardium of control and levosimendan-treated rats. *Denotes a significant difference (<italic>p</italic> &lt; 0.001) between treatment and control groups.</p>
</caption>
<graphic xlink:href="10.1177_0748233712436643-fig2.tif"/>
</fig>
<fig id="fig3-0748233712436643" position="float">
<label>Figure 3.</label>
<caption>
<p>Superoxide dismutase (SOD) enzyme activity in the myocardium of control and levosimendan-treated rats. *Denotes a significant difference (<italic>p</italic> &lt; 0.001) between treatment and control groups.</p>
</caption>
<graphic xlink:href="10.1177_0748233712436643-fig3.tif"/>
</fig>
<fig id="fig4-0748233712436643" position="float">
<label>Figure 4.</label>
<caption>
<p>Glutathione peroxidase (GSH-Px) enzyme activity in the myocardium of control and levosimendan-treated rats. *Denotes a significant difference (<italic>p</italic> &lt; 0.001) between treatment and control groups.</p>
</caption>
<graphic xlink:href="10.1177_0748233712436643-fig4.tif"/>
</fig>
<fig id="fig5-0748233712436643" position="float">
<label>Figure 5.</label>
<caption>
<p>Catalase (CAT) enzyme activity in the myocardium of control and levosimendan-treated rats. *Denotes a significant difference (<italic>p</italic> &lt; 0.001) between treatment and control groups.</p>
</caption>
<graphic xlink:href="10.1177_0748233712436643-fig5.tif"/>
</fig>
<fig id="fig6-0748233712436643" position="float">
<label>Figure 6.</label>
<caption>
<p>Carbonic anhydrase (CA) enzyme activity in the myocardium of control and levosimendan-treated rats. *Denotes a significant difference (<italic>p</italic> &lt; 0.001) between treatment and control groups.</p>
</caption>
<graphic xlink:href="10.1177_0748233712436643-fig6.tif"/>
</fig>
</sec>
<sec id="section7-0748233712436643">
<title>Discussion</title>
<p>This experiment was carried out to investigate the effect of i.p. injection of levosimendan on oxidative stress of myocardium in rats. The pharmacokinetics of levosimendan underpins the prolonged beneficial hemodynamic effects that result from single-dose regime. It is an appealing and promising alternative adjunct to current therapies for cardiac failure. Levosimendan is also of benefit in the setting of pulmonary vasoconstriction and right ventricular dysfunction (<xref ref-type="bibr" rid="bibr11-0748233712436643">Kamath et al., 2009</xref>). Levosimendan increases myofilament sensitivity to Ca<sup>2+</sup> (<xref ref-type="bibr" rid="bibr14-0748233712436643">Levijoki et al., 2000</xref>). It has been shown that levosimendan increases contraction of heart via this mechanism (<xref ref-type="bibr" rid="bibr4-0748233712436643">Edes et al., 1995</xref>). Cardiac myocytes contain two distinct K<sub>ATP</sub> channels: one in sarcolemmal membrane and the other in mitochondrial inner membrane (<xref ref-type="bibr" rid="bibr26-0748233712436643">Sly and Hu, 1995</xref>). Levosimendan has vasodilating properties that reduce cardiac preload and afterload. Vasodilatation is attributed to the opening of K<sub>ATP</sub> channels in the sarcolemmal membrane of vascular smooth muscle. This effect produces both coronary and systemic vasodilatation and coronary blood flow is enhanced (<xref ref-type="bibr" rid="bibr6-0748233712436643">Gross and Fryer, 2000</xref>; <xref ref-type="bibr" rid="bibr15-0748233712436643">Lilleberg et al., 1998</xref>; <xref ref-type="bibr" rid="bibr22-0748233712436643">Pataricza et al., 2003</xref>).</p>
<p>Its interaction, normal myocardial cell functions and integrity of cell structures may be broken via considerable reactivity of ROS. MDA is one of the many products of LPO (<xref ref-type="bibr" rid="bibr5-0748233712436643">Gecit et al., 2011</xref>; <xref ref-type="bibr" rid="bibr16-0748233712436643">Liu et al., 2005</xref>). LPO changes membrane fluidity and enzyme activity (<xref ref-type="bibr" rid="bibr29-0748233712436643">Tuna et al., 2001</xref>). Proteins, membrane lipids and nucleic acids are targets of free radical-mediated injury. Free radicals may act by peroxidation of membrane lipids, inactivation of enzymes by oxidation of sulfhydryl groups, depolymerization of polysaccharides and disruption of nucleic acids (<xref ref-type="bibr" rid="bibr24-0748233712436643">Sayır et al., 2011</xref>).</p>
<p>In the present study, it was found that the LPO products decreased in myocardium after the administration of levosimendan in rats. This indicated that, levosimendan administration may decrease oxidative stress by decreasing free radical production in myocardium. Similar to our result, <xref ref-type="bibr" rid="bibr8-0748233712436643">Hasslacher et al. (2011</xref>) suggested that levosimendan inhibits the release of ROS in polymorphonuclear leukocytes (PMNs) <italic>in vitro</italic> and in patients with acute heart failure and septic shock. They concluded that levosimendan exerts distinct immunomodulatory effects by decreasing oxidative burst activity of PMN. In another study, <xref ref-type="bibr" rid="bibr21-0748233712436643">Parissis et al. (2007</xref>) investigated the effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Consistent with our result, they suggested that levosimendan does not increase the levels of markers of oxidative and nitrosative stress thus, exerting cardioprotective effects in advanced chronic heart failure patients.</p>
<p>Under normal circumstances, varieties of antioxidant defense systems exist to prevent or regulate the formation of these highly reactive and toxic mobilities. These include SOD, GSH-Px, CAT, CA and other free radical scavengers, such as GSH. SOD is an enzyme found in the cytosol and mitochondria. It is responsible for decreasing superoxide levels. GSH-Px is in the mitochondria and cytosol and reduces organic hydroperoxides and hydrogen peroxide in reaction that involves GSH. GSH is not only a cofactor for glutathione <italic>S</italic>-transferase but also serves as a reductant for GSH-Px, an enzyme involved in natural protection by free radicals, in addition to SOD and CAT (<xref ref-type="bibr" rid="bibr2-0748233712436643">Al Hamedan et al., 2011</xref>; <xref ref-type="bibr" rid="bibr13-0748233712436643">Kanno et al., 2004</xref>). CA catalyzes the reversible hydration of carbon dioxide. At least nine enzymatically active mammalian CA isozymes have been identified (<xref ref-type="bibr" rid="bibr26-0748233712436643">Sly and Hu, 1995</xref>; <xref ref-type="bibr" rid="bibr27-0748233712436643">Swenson, 1997</xref>; <xref ref-type="bibr" rid="bibr30-0748233712436643">Tureci et al., 1998</xref>), differing in, for example kinetic parameters, inhibitor binding, tissue distribution and subcellular localization (<xref ref-type="bibr" rid="bibr23-0748233712436643">Şahin et al., 2007</xref>). In this study, the activities of antioxidant enzymes such as SOD, GSH-Px, CAT and CA, and antioxidant GSH level were lower in levosimendan-injected group than in controls. This indicated that antioxidant enzyme activity and free radical scavenger level in myocardium of rat decreased due to the levosimendan injection. Antioxidant enzymes are synthesized in the body to prevent the formation of these highly reactive and toxic moieties. Therefore, it can be said that lower tissue free radical level caused by levosimendan injection led to a lower antioxidant enzymes synthesis in the body. The mechanism by which levosimendan exerts its antioxidant effect is not clear and requires further investigation.</p>
</sec>
<sec id="section8-0748233712436643">
<title>Conclusion</title>
<p>It was concluded that levosimendan injection may decrease oxidative stress by decreasing free radical production in myocardium. It was also concluded that lower level of tissue free radical caused by levosimendan injection led to a lower antioxidant enzymes synthesis in the body and a decrease in the antioxidant enzyme activity and free radical scavenger level in myocardium of rat.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank Dr Sıdık Keskin for his helps in statistical evaluation of our data.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0748233712436643"><label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0748233712436643">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Aebi</surname>
<given-names>H</given-names>
</name>
</person-group> (<year>1974</year>) <article-title>Catalase</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Bergmayer</surname>
<given-names>HU</given-names>
</name>
</person-group> (ed.) <source>Methods of Enzymatic Analysis</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Academic Press Inc</publisher-name>, pp.<fpage>673</fpage>–<lpage>677</lpage>.</citation>
</ref>
<ref id="bibr2-0748233712436643">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Al Hamedan</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Anfenan</surname>
<given-names>MLK</given-names>
</name>
</person-group> (<year>2011</year>) <article-title>Antioxidant activity of leek towards free radical resulting from consumption of carbonated meat in rats</article-title>. <source>Life Science Journal</source> <volume>8</volume>
<issue>(1)</issue>: <fpage>169</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr2a-0748233712436643">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Colledge</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>BR</given-names></name>
<name><surname>Ralston</surname>
<given-names>SH</given-names>
</name>
</person-group> (<year>2010</year>) <source>Davidson’s Principles and Practice of Medicine 21st Edition</source>. <publisher-name>Churchill Livingstone</publisher-name>.</citation>
</ref>
<ref id="bibr3-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durak</surname>
<given-names>İ</given-names>
</name>
<name>
<surname>Canbolat</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kavutcu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oztürk</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Yurtarslanı</surname>
<given-names>Z</given-names>
</name>
</person-group> (<year>1996</year>) <article-title>Activities of total, cytoplasmic, and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer</article-title>. <source>Journal of Clinical Laboratory Analysis</source> <volume>10</volume>: <fpage>17</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr4-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edes</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kitada</surname>
<given-names>Y</given-names>
</name>
</person-group> (<year>1995</year>) <article-title>Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca21 sensitivity of myofibrils and sarcoplasmic reticulum in guinea pig heart</article-title>. <source>Circulation Research</source> <volume>77</volume>: <fpage>107</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr5-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gecit</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kavak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meral</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pirinçci</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Güneş</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Effects of shock waves on oxidative stress, antioxidant enzyme and element levels in kidney of rats</article-title>. <source>Biological Trace Element Research </source>
<volume>144</volume>(<issue>1-3</issue>): <fpage>1069</fpage>–<lpage>1076</lpage>.</citation>
</ref>
<ref id="bibr6-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Fryer</surname>
<given-names>RM</given-names>
</name>
</person-group> (<year>2000</year>) <article-title>Sarcolemmal vs. mitochondrial ATP sensitive K channels and myocardial preconditioning</article-title>. <source>Circulation Research</source> <volume>84</volume>: <fpage>973</fpage>–<lpage>979</lpage>.</citation>
</ref>
<ref id="bibr7-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haikala</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kaivola</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nissinen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Levijoki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>IB</given-names>
</name>
</person-group> (<year>1995</year>) <article-title>Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan</article-title>. <source>Journal of Molecular and Cellular Cardiology</source> <volume>27</volume>: <fpage>1859</fpage>–<lpage>1866</lpage>.</citation>
</ref>
<ref id="bibr8-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasslacher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bijuklic</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bertocchi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kountchev</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bellmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dunzendorfer</surname>
<given-names>S</given-names>
</name>
</person-group>, et al. (<year>2011</year>) <article-title>Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study</article-title>. <source>Critical Care</source> <volume>15</volume>(<issue>4</issue>): <fpage>R166</fpage>.</citation>
</ref>
<ref id="bibr9-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Innes</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Wagstaff</surname>
<given-names>AJ</given-names>
</name>
</person-group> (<year>2003</year>) <article-title>Levosimendan: a review of its use in the management of acute decompensated heart failure</article-title>. <source>Drugs</source> <volume>63</volume>: <fpage>2651</fpage>–<lpage>2671</lpage>.</citation>
</ref>
<ref id="bibr10-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaheinen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pollesello</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Levijoki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haikala</surname>
<given-names>H</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels</article-title>. <source>Journal of Cardiovascular Pharmacology</source> <volume>37</volume>: <fpage>367</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr11-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamath</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Jaykumar</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Matha</surname>
<given-names>S</given-names>
</name>
</person-group> (<year>2009</year>) <article-title>Levosimendan</article-title>. <source>Indian Pediatrics</source> <volume>46</volume>: <fpage>593</fpage>–<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr12-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Epsteın</surname>
<given-names>PN</given-names>
</name>
</person-group> (<year>1996</year>) <article-title>Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice</article-title>. <source>The Journal of Biological Chemistry</source> <volume>271</volume>: <fpage>12610</fpage>–<lpage>12616</lpage>.</citation>
</ref>
<ref id="bibr13-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Muranaka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fujiwara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Utsumi</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Oxidative stress underlies the mechanism for Ca<sup>2+</sup>-induced permeability transition of mitochondria</article-title> <source>Free Radical Research</source> <volume>38</volume>(<issue>1</issue>): <fpage>27</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr14-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levijoki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pollesello</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaivola</surname>
<given-names>J</given-names>
</name>
</person-group> (<year>2000</year>) <article-title>Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure–response and binding analyses with analogs of levosimendan</article-title>. <source>Journal of Molecular and Cellular Cardiology</source> <volume>32</volume>: <fpage>479</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr15-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lilleberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nieminen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Akkila</surname>
<given-names>J</given-names>
</name>
</person-group> (<year>1998</year>) <article-title>Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting</article-title>. <source>European Heart Journal</source> <volume>19</volume>: <fpage>660</fpage>–<lpage>668</lpage>.</citation>
</ref>
<ref id="bibr16-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>QB</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>ZG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>ZP</given-names>
</name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Protective effects of <italic>Rheum tanguticum</italic> polysaccharide against hydrogen peroxide-induced intestinal epithelial cell injury</article-title>. <source>World Journal of Gastroenterology</source> <volume>11</volume>(<issue>10</issue>): <fpage>1503</fpage>–<lpage>1507</lpage>.</citation>
</ref>
<ref id="bibr17-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markova</surname>
<given-names>OO</given-names>
</name>
<name>
<surname>Mysula</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Bodnar</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Kvik</surname>
<given-names>II</given-names>
</name>
<name>
<surname>Borys</surname>
<given-names>AP</given-names>
</name>
</person-group> (<year>1995</year>) <article-title>The content of macro- and trace elements in the cardiac muscle of adult and old rats after stressor influence</article-title>. <source>Fiziolohichnyi Zhurnal</source>
<volume> 41</volume>(<issue>1-2</issue>): <fpage>100</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr19-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arner</surname>
<given-names>ESJ</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>Reactive oxygen species, antioxidants, and mammalian thioredoxin system</article-title>. <source>Free Radical Biology and Medicine</source> <volume>31</volume>: <fpage>1287</fpage>–<lpage>1312</lpage>.</citation>
</ref>
<ref id="bibr20-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Özer</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Kaman</surname>
<given-names>D</given-names>
</name>
</person-group> (<year>2007</year>) <article-title>Effects of epigallocatechin 3-gallate in rat cardiac tissue on oxidant and antioxidant system exposed to sevoflurane anesthesia</article-title>. <source>Fırat Tıp Dergisi</source> <volume>12</volume>(<issue>2</issue>): <fpage>93</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr21-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parissis</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Andreadou</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Markantonis</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bistola</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Louka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pyriochou</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure</article-title>. <source>Atherosclerosis</source> <volume>195</volume>(<issue>2</issue>): <fpage>e210</fpage>–<lpage>e215</lpage>.</citation>
</ref>
<ref id="bibr22-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pataricza</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krassoi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hohn</surname>
<given-names>J</given-names>
</name>
</person-group> (<year>2003</year>) <article-title>Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery</article-title>. <source>Cardiovascular Pharmacology and Therapy</source> <volume>17</volume>: <fpage>115</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr23-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Şahin</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Görmüş</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>A</given-names>
</name>
</person-group> (<year>2007</year>) <article-title>Preconditioning with levosimendan prevents contractile dysfunction due to H2O2-induced oxidative stress in human myocardium</article-title>. <source>Journal of Cardiovascular Pharmacology</source> <volume>50</volume>: <fpage>419</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr24-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayır</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kavak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meral</surname>
<given-names>İ</given-names>
</name>
<name>
<surname>Demir</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cengiz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Çobanoğlu</surname>
<given-names>U</given-names>
</name>
</person-group> (<year>2011</year>) <article-title>Effects of crush and axotomy on oxidative stress and some trace element levels in phrenic nerve of rats</article-title>. <source>Brain Research Bulletin</source>. <comment>Epub ahead of print 23 July 2011</comment>.</citation>
</ref>
<ref id="bibr25-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedlak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>RHC</given-names>
</name>
</person-group> (<year>1968</year>) <article-title>Estimation of total, protein bound and non-protein sulfhydryl groups in tissue with Ellmann’s reagent</article-title>. <source>Analytical Biochemistry</source> <volume>25</volume>: <fpage>192</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr26-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sly</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>PY</given-names>
</name>
</person-group> (<year>1995</year>) <article-title>Human carbonic anhydrases and carbonic anhydrase deficiencies</article-title>. <source>Annual Review of Biochemistry</source> <volume>64</volume>: <fpage>375</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr27-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swenson</surname>
<given-names>ER</given-names>
</name>
</person-group> (<year>1997</year>) <article-title>Carbonic anhydrase and the heart</article-title>. <source>Cardiologia</source> <volume>42</volume>: <fpage>453</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr28-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Topçuoglu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Uzun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Balci</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Karakus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Çoban</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Altug</surname>
<given-names>T</given-names>
</name>
</person-group>, et al. (<year>2009</year>) <article-title>Effects of estrogens on oxidative protein damage in plasma and tissues in ovariectomised rats</article-title>. <source>Clinical and Investigative Medicine</source> <volume>32</volume>(<issue>2</issue>): <fpage>E133</fpage>–<lpage>E143</lpage>.</citation>
</ref>
<ref id="bibr29-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Polat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Erman</surname>
<given-names>T</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>Effect of anti-rat interleukin-6 antibody after spinal cord injury in the rat: inducible nitric oxide synthase expression, sodium- and potassium-activated, magnesium-dependent adenosine-50-triphosphatase and superoxide dismutase activation, and ultrastructural changes</article-title>. <source>Journal of Neurosurgery</source> <volume>95</volume>: <fpage>64</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr30-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tureci</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Vollmar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Siemer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gottert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Seitz</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>95</volume>: <fpage>7608</fpage>–<lpage>7613</lpage>.</citation>
</ref>
<ref id="bibr31-0748233712436643">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Yagi</surname>
<given-names>K</given-names>
</name>
</person-group> (<year>1994</year>) <article-title>Lipid peroxides and related radicals in clinical medicine</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Armstrong</surname>
<given-names>D</given-names>
</name>
</person-group> (ed.) <source>Free Radicals in Diagnostic Medicine. </source>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Plenum</publisher-name>, pp.<fpage>1</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr32-0748233712436643">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yazar</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Konyalıoglu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Col</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bırdane</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Levent Bas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elmas</surname>
<given-names>M</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>Effects of vitamin E and prednisolone on some oxidative stress markers in endotoxemic rabbits</article-title>. <source>Revue de Médecine Vétérinaire</source> <volume>155</volume>
<issue>(11)</issue> <fpage>538</fpage>–<lpage>542</lpage>. </citation>
</ref>
</ref-list>
</back>
</article>